AGR Summary
Alnylam Pharmaceuticals, Inc.
(NASD:ALNY)
Conservative
(88)
| Industry: | Biotechnology | Period End: | Mar 31, 2010 (Fiscal 2010 Q-1) | Statement Filing: | May 5, 2010 (10-Q) |
|---|---|---|---|---|---|
| Market Cap: | USD 578.0mm (Small Cap) | Last Audit: | PriceWaterhouseCoopers LLP | Rating Published: | Jun 18, 2010 |
OVERVIEW
Alnylam Pharmaceuticals, Inc.
is currently rated as having
Conservative Accounting & Governance Risk (AGR).
This places them in the 88th
percentile among all companies, indicating higher accounting and governance risk than
12% of companies.
RISK SUMMARY
The forensic risk summary highlights material risks, if any, and lists the most material red flagged metric for each risk. AGR Impact shows the relative weight of the various red flagged metrics by risk type.
| Risk | AGR Impact | Top Flagged Metric |
|---|---|---|
| Corporate Governance Events | 0.0% | |
| High Risk Events | 0.0% | |
| Revenue Recognition | 0.0% | |
| Expense Recognition | 31.0% | Depreciation Expenses/PPE |
| Asset-Liability Valuation | 69.0% | Asset Turnover |